Pioglitazone and empagliflozin for fatty liver in type 2 diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have type 2 diabetes with an A1c between 7% and 10% (a blood sugar average over 3 months).
- You take metformin alone or with a sulfonylurea or a DPP-4 inhibitor (common diabetes pills).
- A liver scan within the last 3 months showed you have fatty liver (a score of 268 or higher on a FibroScan).
- You have at least one of: large waist size, high blood pressure (or taking medicine for it), high triglycerides (or taking medicine for them), low HDL cholesterol, high insulin resistance, or high C-reactive protein (a sign of inflammation).
- You have not changed your diabetes or metabolic medications in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
This study compares two diabetes medications, dapagliflozin and empagliflozin, to see which is more effective, safe, and affordable for people with type 2 diabetes and a high body weight. Both medications help lower blood sugar and may also help with weight loss.
This study tests whether adding dapagliflozin (a diabetes drug) to metformin can lower a growth factor (IGF-1) that may affect fatty liver disease in men. It aims to see if this combined treatment improves liver health and diabetes control.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.